FDA drops enforcement against Whoop after it tweaks blood pressure feature | STAT
Skip to Main Content
My Account
A decade of reporting from the frontiers of health and medicine
Search
Log In
Try STAT+
My Account
News
Latest
Series & Investigations
Business
Biotech
Pharma
Health Tech
Health Insurance
Hospitals
Medical Devices
Washington
Policy
FDA
NIH
Science
CRISPR
Gene Therapy
Neuroscience
Public Health
Addiction
Covid-19
Abortion
Health Disparities
Infectious Disease
Mental Health
Disease
Cancer
Cardiovascular Disease
Chronic Disease
Diabetes
Alzheimer's
Obesity
Features
The Deadliest Drug
Science, Shattered
The MAHA Diagnosis
Newsletters
Opinion
Columns
Adam Feuerstein
Matthew Herper
Ed Silverman
Reports
E-books
Podcasts
Tools & Trackers
CRISPR Tracker
Breakthrough Device Tracker
Generative AI Tracker
Obesity Drug Tracker
Events
Upcoming Events
Summits
Community
STAT Wunderkinds 2026
Video
Advertise
STAT Brand Studio
What's the word?<br>Test your knowledge with our new weekday mini crossword
Start solving
STAT Plus<br>Breaking News
FDA drops enforcement against Whoop after it tweaks blood pressure feature
The agency’s updated wellness guidance remains ambiguous and poses risks to users, experts say
Manage alerts for this article
Email this article
Share this article
Courtesy Whoop
By Mario Aguilar<br>June 23, 2026
Health Tech Correspondent
Mario Aguilar
[email protected]
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
The Food and Drug Administration quietly told wearable maker Whoop last week that it would not take further enforcement action over a controversial feature that gives users a reading of their blood pressure.
In July 2025, the agency warned Whoop for releasing its Blood Pressure Insights feature without clearance, saying it was a medical device that required review. “The product is intended to provide a measurement or estimation of a user’s blood pressure, which is inherently associated with the diagnosis of hypo- and hypertension,” the agency wrote.<br>Advertisement
Whoop countered that the feature could be released without review because it was intended for wellness purposes and not to diagnose or treat a disease. “We won’t let regulatory overreach dictate how people access their own health data,” CEO Will Ahmed wrote at the time.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
Monthly
$39
Totals $468 per year
$39/month<br>Get Started<br>Totals $468 per year
Starter
$30
for 3 months, then $399/year
$30 for 3 months<br>Get Started<br>Then $399/year
Annual
$399
Save 15%
$399/year<br>Get Started<br>Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote<br>Request A Quote<br>Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year<br>Get Started<br>$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Log In
FDA, health tech, Policy, STAT+, wearables
Submit a correction requestReprints
Mario Aguilar
Health Tech Correspondent
Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer wearables. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
Please enter a valid email address.<br>Sign Up
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
Recommended
Biotech
Biotech<br>June 22, 2026
STAT Plus: FDA to launch pilot program to speed up early-stage clinical trials
Biotech
Biotech<br>June 17, 2026
STAT Plus: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval
Advertisement
Politics
Politics<br>June 9, 2026
STAT Plus: NIAID appoints new acting director after weekslong questions over leadership
Health
Health<br>June 1, 2026
STAT Plus: Trump administration releases rules for new Medicaid work requirements
Exclusive
Exclusive<br>May 29, 2026
STAT Plus: Massachusetts sues UnitedHealth, alleging fraud in state’s Medicaid plans for seniors
Subscriber Picks
Back to top